BACKGROUND: The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy. Both IPT and highly active antiretroviral therapy (HAART) used separately result in reductions in tuberculosis risk. There is less information on the combined effect of IPT and HAART. We assessed the effect of IPT, HAART or both IPT and HAART on tuberculosis incidence in HIV-infected adults in South Africa. METHODS: Two clinical cohorts of HIV-infected patients were studied. Primary exposures were receipt of IPT and/or HAART and the primary outcome was incident tuberculosis. Crude incident rates and incident rate ratios were calculated and Cox proportional hazards models investigated associations with tuberculosis risk. RESULTS: Among 2778 HIV-infected patients followed for 4287 person-years, 267 incident tuberculosis cases were diagnosed [incidence rate ratio (IRR)=6.2/100 person-years; 95% CI 5.5-7.0]. For person-time without IPT or HAART, the IRR was 7.1/100 person-years (95% CI 6.2-8.2); for person-time receiving HAART but without IPT, the IRR was 4.6/100 person-years (95% CI 3.4-6.2); for person-time after IPT but prior to HAART, the IRR was 5.2/100 person-years (95% CI 3.4-7.8); during follow-up in patients treated with HAART after receiving IPT the IRR was 1.1/100 person-years (95% CI 0.02-7.6). Compared to treatment-naive patients, HAART-only patients had a 64% decreased hazard for tuberculosis [adjusted hazard ratio (aHR)=0.36; 95% CI 0.25-0.51], and patients receiving HAART after IPT had a 89% reduced hazard (aHR=0.11; 95% CI 0.02-0.78). CONCLUSION: Tuberculosis risk is significantly reduced by IPT in HAART-treated adults in a high-incidence operational setting in South Africa. IPT is an inexpensive and cost-effective strategy and our data strengthen calls for the implementation of IPT in conjunction with the roll-out of HAART.
BACKGROUND: The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy. Both IPT and highly active antiretroviral therapy (HAART) used separately result in reductions in tuberculosis risk. There is less information on the combined effect of IPT and HAART. We assessed the effect of IPT, HAART or both IPT and HAART on tuberculosis incidence in HIV-infected adults in South Africa. METHODS: Two clinical cohorts of HIV-infectedpatients were studied. Primary exposures were receipt of IPT and/or HAART and the primary outcome was incident tuberculosis. Crude incident rates and incident rate ratios were calculated and Cox proportional hazards models investigated associations with tuberculosis risk. RESULTS: Among 2778 HIV-infectedpatients followed for 4287 person-years, 267 incident tuberculosis cases were diagnosed [incidence rate ratio (IRR)=6.2/100 person-years; 95% CI 5.5-7.0]. For person-time without IPT or HAART, the IRR was 7.1/100 person-years (95% CI 6.2-8.2); for person-time receiving HAART but without IPT, the IRR was 4.6/100 person-years (95% CI 3.4-6.2); for person-time after IPT but prior to HAART, the IRR was 5.2/100 person-years (95% CI 3.4-7.8); during follow-up in patients treated with HAART after receiving IPT the IRR was 1.1/100 person-years (95% CI 0.02-7.6). Compared to treatment-naive patients, HAART-only patients had a 64% decreased hazard for tuberculosis [adjusted hazard ratio (aHR)=0.36; 95% CI 0.25-0.51], and patients receiving HAART after IPT had a 89% reduced hazard (aHR=0.11; 95% CI 0.02-0.78). CONCLUSION:Tuberculosis risk is significantly reduced by IPT in HAART-treated adults in a high-incidence operational setting in South Africa. IPT is an inexpensive and cost-effective strategy and our data strengthen calls for the implementation of IPT in conjunction with the roll-out of HAART.
Authors: C C Whalen; J L Johnson; A Okwera; D L Hom; R Huebner; P Mugyenyi; R D Mugerwa; J J Ellner Journal: N Engl J Med Date: 1997-09-18 Impact factor: 91.245
Authors: N A Halsey; J S Coberly; J Desormeaux; P Losikoff; J Atkinson; L H Moulton; M Contave; M Johnson; H Davis; L Geiter; E Johnson; R Huebner; R Boulos; R E Chaisson Journal: Lancet Date: 1998-03-14 Impact factor: 79.321
Authors: A Mwinga; M Hosp; P Godfrey-Faussett; M Quigley; P Mwaba; B N Mugala; O Nyirenda; N Luo; J Pobee; A M Elliott; K P McAdam; J D Porter Journal: AIDS Date: 1998-12-24 Impact factor: 4.177
Authors: Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye Journal: Proc Natl Acad Sci U S A Date: 2010-10-25 Impact factor: 11.205
Authors: Salome Charalambous; Alison D Grant; Craig Innes; Christopher J Hoffmann; Rob Dowdeswell; Jan Pienaar; Katherine L Fielding; Gavin J Churchyard Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson Journal: AIDS Date: 2011-01-02 Impact factor: 4.177
Authors: Suzue Saito; Philani Mpofu; E Jane Carter; Lameck Diero; Kara K Wools-Kaloustian; Constantin T Yiannoutsos; Musick S Beverly; Simon Tsiouris; Geoffrey R Somi; John Ssali; Denis Nash; Batya Elul Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Jason E Farley; Timothy F Landers; Catherine Godfrey; Virginia Lipke; Jeremy Sugarman Journal: J Acquir Immune Defic Syndr Date: 2014-01-01 Impact factor: 3.731